Subject(s)
Rheumatic Diseases , Travel , Humans , Rheumatic Diseases/diagnosis , Rheumatic Diseases/therapyABSTRACT
OBJECTIVES: To evaluate the influence of the SARS-CoV-2 pandemic on the adherence of patients with inflammatory rheumatic diseases (IRD) to their immunomodulatory medication during the three-month lockdown in Germany. METHODS: From 16th March until 15th June 2020, IRD patients from private practices and rheumatology departments were asked to answer a questionnaire addressing their behaviour with respect to their immunomodulating therapy. Eight private practices and nine rheumatology departments that included rheumatology primary care centres and university hospitals participated. A total of 4252 questionnaires were collected and evaluated. RESULTS: The majority of patients (54%) were diagnosed with RA, followed by psoriatic arthritis (14%), ankylosing spondylitis (10%), connective tissue diseases (12%) and vasculitides (6%). Most of the patients (84%) reported to continue their immunomodulatory therapy. Termination of therapy was reported by only 3% of the patients. The results were independent from the type of IRD, the respective immunomodulatory therapy and by whom the patients were treated (private practices vs rheumatology departments). Younger patients (<60 years) reported just as often as older patients to discontinue their therapy. CONCLUSION: The data show that most of the patients continued their therapy in spite of the pandemic. A significant change in behaviour with regard to their immunomodulatory therapy was not observed during the three months of observation. The results support the idea that the immediate release of recommendations of the German Society of Rheumatology were well received, supporting the well-established physician-patient relationship in times of a crisis.
Subject(s)
COVID-19/prevention & control , Drug Prescriptions/statistics & numerical data , Medication Adherence/statistics & numerical data , Practice Patterns, Physicians'/statistics & numerical data , Quarantine/statistics & numerical data , Rheumatic Diseases/drug therapy , Adult , Antirheumatic Agents/therapeutic use , Cross-Sectional Studies , Female , Germany , Humans , Immunologic Factors/therapeutic use , Male , Middle Aged , SARS-CoV-2Subject(s)
Rheumatic Diseases , Rheumatology , Humans , Rheumatic Diseases/diagnosis , Rheumatic Diseases/therapyABSTRACT
BACKGROUND: The development of rheumatology into one of the most progressive medical disciplines is mainly based on the enormous scientific knowledge gained in recent decades. Physician scientists have played a substantial role in this development. With respect to the ongoing challenges, physician scientists will be urgently needed in the future. Therefore, young physicians need to be attracted to scientific research in rheumatology. OBJECTIVE: This article describes possible paths into academic rheumatology, highlights facilitators and barriers to a scientific career and discusses ideas for the recruitment of young scientists for rheumatology based on the existing literature. RESULTS AND DISCUSSION: It is without doubt that young scientists are urgently needed in rheumatology; however, the number of young physician scientists seems to be declining. The paths to academic rheumatology are manifold and variable but setting the course early on during medical school by science-oriented teaching, research internships and doctoral theses, appears to be advantageous. Favorable factors for the decision to pursue an academic career in rheumatology are enjoyment in research, recognition of research rotations for rheumatology training and improved career opportunities. The greatest barriers are considered to be the exemption from clinical duties as well as lack of experience with scientific methods and acquisition of research funding. Therefore, it is important to make potential scientists enthusiastic about the research underlying modern rheumatology and to encourage research during medical school in order to attract young people to academic rheumatology.
Subject(s)
Rheumatology , Biomedical Research , Humans , Longitudinal Studies , PhysiciansABSTRACT
Systemic disease demands systemic thinkers. In this mission statement we define rheumatology, describe the role of the German Society of Rheumatology and the rheumatologist's spirit to their discipline. Rheumatologists are dedicated to improving the quality of life of their acute, chronic, and rehabilitative patients on the basis of up to date evidence and strong physician-patient relations. We think, act and interact systemically, scientifically, consistently, transparently, reliably, inclusively, innovatively and enthusiastically.
Subject(s)
Rheumatologists , Rheumatology , Humans , Physician-Patient Relations , Quality of Life , Societies, MedicalABSTRACT
Systemic disease demands systemic thinkers. In this mission statement we define rheumatology, describe the role of the German Society of Rheumatology and the rheumatologist's spirit to their discipline. Rheumatologists are dedicated to improving the quality of life of their acute, chronic, and rehabilitative patients on the basis of up to date evidence and strong physician-patient relations. We think, act and interact systemically, scientifically, consistently, transparently, reliably, inclusively, innovatively and enthusiastically.
Subject(s)
Physician-Patient Relations , Rheumatologists , Rheumatology , Germany , Humans , Patient-Centered Care , Quality of LifeABSTRACT
The recommendations of the German Society of Rheumatology (DGRh) update, which update and expand the guidance on the management of patients with inflammatory rheumatic diseases in view of SARS-CoV2 created at the beginning of the COVID-19 pandemic, correspond in many points with the recommendations for action of the American (ACR) and European (EULAR) societies, but also differ in some points. Therefore, this article discusses the core recommendations of the DGRh update on the prevention of SARS-CoV-2/COVID-19, the risk assessment for inflammatory rheumatic diseases and the use of antirheumatic treatments in the context and in comparison to the ACR and EULAR recommendations, and provides an overview of the risk assessment of individual antirheumatic drugs.
Subject(s)
Antirheumatic Agents/therapeutic use , Coronavirus Infections/epidemiology , Inflammation/therapy , Pneumonia, Viral/epidemiology , Rheumatic Diseases/therapy , Rheumatology , Betacoronavirus , COVID-19 , Europe , Germany , Humans , Pandemics , Practice Guidelines as Topic , Risk Assessment , SARS-CoV-2 , Societies, Medical , United StatesABSTRACT
In the current SARS-CoV-2 pandemic there are many questions regarding the safe treatment of patients with inflammatory rheumatic diseases. Many of these questions cannot yet be answered on an evidence-based basis and this does not make patient care easy. The German Society for Rheumatology (DGRh) hopes that these initial recommendations will provide support for specific issues in the care of patients with inflammatory rheumatic diseases in view of the current threat posed by SARS-CoV-2. In order to take advantage of the dynamic worldwide gain in knowledge for our patients, the recommendations will be updated regularly. The updated versions of the recommendations are deposited on the homepage of the DGRh.
Subject(s)
Betacoronavirus , Coronavirus Infections/complications , Pneumonia, Viral/complications , Rheumatic Diseases , Rheumatology , COVID-19 , Guidelines as Topic , Humans , Immunosuppressive Agents/therapeutic use , Pandemics , Rheumatic Diseases/complications , Rheumatic Diseases/drug therapy , Rheumatic Diseases/immunology , Rheumatology/standards , SARS-CoV-2 , Societies, MedicalABSTRACT
STUDY QUESTION: Is birth weight for gestational age associated with infertility in adulthood among men and women? SUMMARY ANSWER: Being born small for gestational age (SGA) was associated with infertility in adulthood among men. WHAT IS KNOWN ALREADY: Fetal growth restriction may affect fertility, but results from previous studies have been inconsistent. STUDY DESIGN, SIZE, DURATION: In this population-based cohort study, we used data from a Danish birth cohort, including 5594 men and 5342 women born between 1984 and 1987. Information on infertility was obtained from Danish health registers during the period from the participants' 18th birthday and up until 31 December 2017. PARTICIPANTS/MATERIALS, SETTING, METHODS: Participants were men and women born in two Danish municipalities, Aalborg and Odense. Information on birth weight and gestational age was obtained from birth records, and information on infertility diagnoses and fertility treatment was retrieved from the Danish National Patient Registry (NPR) and the Danish In Vitro Fertilisation (IVF) registry. Information on potential maternal confounders was obtained from questionnaires during pregnancy and was included in adjusted analyses. Logistic regression analysis was used to estimate crude and adjusted odds ratios (ORs) with 95% confidence intervals (CIs) for infertility according to birth weight for gestational age. MAIN RESULTS AND THE ROLE OF CHANCE: Men born SGA had a 55% higher risk of being diagnosed with or treated for infertility compared to men born appropriate for gestational age (AGA) (adjusted OR = 1.55, 95% CI: 1.09-2.21). The association attenuated after exclusion of men born with hypospadias or cryptorchidism (OR = 1.37, 95% CI: 0.93-2.01). No association was found between women's birth weight for gestational age and risk of infertility (adjusted OR = 1.00, 95% CI: 0.73-1.37). LIMITATIONS, REASONS FOR CAUTION: Estimation of gestational age is associated with some uncertainty and might have caused non-differential misclassification. The study design implicitly assumed similar distribution of reproductive and health-seeking behaviour across the groups that were compared. WIDER IMPLICATIONS OF THE FINDINGS: Men born SGA had a higher risk of infertility. Genital malformations may account for part of the observed association, but this must be explored further. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by Health, Aarhus University. No competing interests are declared. TRIAL REGISTRATION NUMBER: N/A.
Subject(s)
Infertility , Adult , Birth Weight , Cohort Studies , Denmark/epidemiology , Female , Gestational Age , Humans , Infertility/epidemiology , Male , PregnancyABSTRACT
Among the eosinophilic diseases treated by rheumatologists other than eosinophilic granulomatosis with polyangiitis, there are further organ-related and systemic diseases with hypereosinophilia. Only the exact differential diagnostic demarcation of the diseases enables a pathogenetic oriented treatment. This article focuses on the hypereosinophilic syndromes. The potential differential diagnoses of Ig(immunoglobulin)G4-related disease, eosinophilic fasciitis and drug-induced vasculitis as well as eosinophilia-myalgia syndrome and toxic oil syndrome as historic drug-induced inflammatory rheumatic diseases are described and the clinical manifestations and treatment are summarized.
Subject(s)
Eosinophilia , Fasciitis , Hypereosinophilic Syndrome , Rheumatic Diseases , Diagnosis, Differential , Eosinophilia/diagnosis , Fasciitis/diagnosis , Humans , Hypereosinophilic Syndrome/complications , Hypereosinophilic Syndrome/diagnosis , Rheumatic Diseases/complications , Rheumatic Diseases/diagnosisABSTRACT
We studied the association between intake of non-prescription analgesics and semen quality and male reproductive hormone levels in a cross-sectional study among 1493 men. The men provided one semen (n=1493) and blood sample (n=1056) and filled in questionnaires on use of non-prescription analgesics (paracetamol, NSAIDs and combination drugs (yes/no)). Adjusting for age, study and other covariates, we observed no association between intake of non-prescription analgesics and markers of semen quality. Adjusting for age and time of day of blood sampling, users of non-prescription analgesics had a 10.4% (95% confidence interval (CI) 4.0-17.1%) higher testosterone level than non-users. When we stratified by medication type, the association between analgesics and higher testosterone was observed between users of non-steroidal anti-inflammatory drugs (NSAIDs) and combination drugs but not paracetamol. This study suggests that use of non-prescription analgesics is associated with slightly higher serum testosterone levels than non-use.
Subject(s)
Analgesics/toxicity , Anti-Inflammatory Agents, Non-Steroidal/toxicity , Nonprescription Drugs/toxicity , Testosterone/blood , Adult , Europe , Greenland , Humans , Male , Middle Aged , Semen/drug effectsSubject(s)
B-Lymphocytes/immunology , Cytokines/immunology , Immunotherapy/methods , Molecular Targeted Therapy/methods , Rheumatic Diseases/immunology , Rheumatic Diseases/therapy , B-Lymphocytes/drug effects , Evidence-Based Medicine , Humans , Models, Immunological , Rheumatic Diseases/pathology , Treatment OutcomeABSTRACT
Systemic lupus erythematosus (SLE) can be a mysterious disease, presenting with extremely divergent clinical phenotypes. Already, biomarkers are very helpful tools for diagnosis, assessment and monitoring of disease activity, differential diagnosis of clinical manifestations, prediction of the disease course and stratified therapy, and they hold the key to personalized medicine in SLE. We summarize the clinical information that can only be supplied by autoantibodies, complement components and interferon biomarkers in this diverse disease.
Subject(s)
Autoantibodies/blood , Complement System Proteins/analysis , Interferon Type I/blood , Lupus Erythematosus, Systemic/blood , Lupus Erythematosus, Systemic/diagnosis , Biomarkers/blood , Humans , Lupus Erythematosus, Systemic/drug therapy , Precision Medicine , Severity of Illness IndexABSTRACT
Immunomodulatory therapy is the gold standard in the treatment of autoimmune diseases. Increasing knowledge of the underlying mechanisms leading to autoimmunity enables patients to be treated with better and more specific therapies apart from the classical therapies, such as antimalarial drugs and glucocorticoids. For patients this nowadays means a great chance to receive optimized therapy. Numerous treatment options have been developed over the last decades and the development of new treatment approaches and strategies is still ongoing. This review gives an overview of immunomodulatory therapy approaches.
Subject(s)
Autoimmune Diseases/immunology , Autoimmune Diseases/therapy , Eye Diseases/immunology , Eye Diseases/therapy , Immunologic Factors/administration & dosage , Immunosuppressive Agents/administration & dosage , Antibodies, Monoclonal/administration & dosage , Autoimmune Diseases/diagnosis , Diagnosis, Differential , Evidence-Based Medicine , Eye Diseases/diagnosis , Humans , Immunomodulation , Practice Patterns, Physicians'/trends , Treatment OutcomeABSTRACT
This article presents a particularly severe case of adult onset Still's disease aggravated by small vessel vasculitis. A satisfactory therapy was concluded 1.5 years after onset of the disease. The small vessel vasculitis was difficult to treat: methotrexate (MTX), cyclophosphamide and rituximab were not sufficiently effective. Tocilizumab in combination with intravenous immunoglobulin (IVIG) induced remission and maintenance therapy was carried out with tocilizumab.
Subject(s)
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/drug therapy , Antibodies, Monoclonal, Humanized/administration & dosage , Immunoglobulins, Intravenous/administration & dosage , Still's Disease, Adult-Onset/complications , Still's Disease, Adult-Onset/drug therapy , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/complications , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/diagnosis , Drug Administration Schedule , Drug Therapy, Combination , Humans , Immunosuppressive Agents/administration & dosage , Male , Still's Disease, Adult-Onset/diagnosis , Treatment Outcome , Young AdultABSTRACT
BACKGROUND: Improved understanding of the immunopathogenesis of systemic lupus erythematosus (SLE) has paved the way for new specific immune interventions for this inflammatory disease similar to those for rheumatoid arthritis and spondylarthritides. METHODS: New biologics were developed on this basis or are in the process of clinical development and open up new therapy options for patients. In this context belimumab is of particular importance. As an innovative biologic the monoclonal antibody against the cytokine BAFF/BLyS (belimumab) has been approved for the treatment of serologically active SLE. A number of other biologics against other cytokines are in the clinical development phase and appear to be promising for further improvement of the current therapeutic possibilities in SLE. This article addresses the current aspects of immune interventions with biologics for SLE and the specific challenges of this disease.
Subject(s)
Antibodies, Monoclonal/administration & dosage , Biological Products/administration & dosage , Immunosuppressive Agents/administration & dosage , Lupus Erythematosus, Systemic/diagnosis , Lupus Erythematosus, Systemic/drug therapy , Evidence-Based Medicine , Humans , Treatment OutcomeABSTRACT
BACKGROUND: Emerging evidence suggests that prenatal or early-life exposures to environmental contaminants may contribute to an increased risk of asthma and allergies in children. We aimed to the explore associations of prenatal exposures to a large set of environmental chemical contaminants with asthma and eczema in school-age children. METHODS: We studied 1024 mother-child pairs from Greenland and Ukraine from the INUENDO birth cohort. Data were collected by means of an interview-based questionnaire when the children were 5-9 years of age. Questions from the ISAAC study were used to define asthma, eczema, and wheeze. We applied principal components analysis (PCA) to sixteen contaminants in maternal serum sampled during pregnancy, including perfluoroalkyl substances (PFASs), metabolites of diethylhexyl (DEHP) and diisononyl (DiNP) phthalates, PCB-153, and p,p'-DDE. Scores of five principal components (PCs) explaining 70% of the variance were included in multiple logistic regression models. RESULTS: In a meta-analysis that included both populations, the PC2 score, reflecting exposure to DiNP, was negatively associated with current eczema (OR 0.71, 95% CI 0.52-0.96). Other associations were not consistent between the two populations. In Ukrainian children, the PC3 score (DEHP) was positively associated with current wheeze (adjusted OR 1.56, 95% CI 1.03-2.37), whereas the PC5 score, dominated by perfluorooctanoic acid (PFOA), was inversely associated with current wheeze (OR 0.64, 0.41-0.99). In Greenlandic children, a negative association of PC4 (organochlorines) with ever eczema (OR 0.78, 0.61-0.99) was found. CONCLUSIONS: We found limited evidence to support a link between prenatal exposure to environmental chemical contaminants and childhood asthma and eczema.
